Published in Int J Technol Assess Health Care on July 08, 2011
Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry (2012) 0.97
Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries. Eur Child Adolesc Psychiatry (2014) 0.81
Caregiver Treatment Preferences for Children with a New Versus Existing Attention-Deficit/Hyperactivity Disorder Diagnosis. J Child Adolesc Psychopharmacol (2016) 0.75
Women's Preferences for Treatment of Perinatal Depression and Anxiety: A Discrete Choice Experiment. PLoS One (2016) 0.75
Increased risk for irritable bowel syndrome after acute diverticulitis. Clin Gastroenterol Hepatol (2013) 4.24
Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry (2012) 2.14
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy (2012) 2.06
The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr (2012) 1.73
A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med (2012) 1.67
The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol (2004) 1.62
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs (2013) 1.58
Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin Gastroenterol Hepatol (2013) 1.35
Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther (2011) 1.28
Under diagnosis of adult ADHD: cultural influences and societal burden. J Atten Disord (2012) 1.17
Genome-wide discovery of functional transcription factor binding sites by comparative genomics: the case of Stat3. Proc Natl Acad Sci U S A (2009) 1.16
Fundamental dimensions of subjective state in performance settings: task engagement, distress, and worry. Emotion (2002) 1.10
Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry (2013) 1.03
Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program. Clin Ther (2012) 1.01
Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative study. Health Qual Life Outcomes (2012) 1.01
Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. Am Heart J (2009) 1.00
Levels of neonatal thyroid hormone in preterm infants and neurodevelopmental outcome at 5 1/2 years: millennium cohort study. J Clin Endocrinol Metab (2010) 0.98
Impact of omalizumab on quality-of-life outcomes in patients with moderate-to-severe allergic asthma. Ann Allergy Asthma Immunol (2006) 0.95
The RhoU/Wrch1 Rho GTPase gene is a common transcriptional target of both the gp130/STAT3 and Wnt-1 pathways. Biochem J (2009) 0.94
Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin (2010) 0.93
Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry (2012) 0.93
The decisions regarding ADHD management (DRAMa) study: uncertainties and complexities in assessment, diagnosis and treatment, from the clinician's point of view. Eur Child Adolesc Psychiatry (2011) 0.92
Estimation of utilities in attention-deficit hyperactivity disorder for economic evaluations. Patient (2011) 0.90
Adult ADHD patient experiences of impairment, service provision and clinical management in England: a qualitative study. BMC Health Serv Res (2013) 0.89
The immediate early genes Fos and Egr1 become STAT1 transcriptional targets in the absence of STAT3. FEBS Lett (2011) 0.89
Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. CNS Drugs (2012) 0.89
ADHD burden of illness in older adults: a life course perspective. Qual Life Res (2011) 0.89
Continuous retrograde blood cardioplegia is associated with lower hospital mortality after heart valve surgery. J Thorac Cardiovasc Surg (2003) 0.88
Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child Adolesc Psychiatry Ment Health (2009) 0.88
Distinguishing comorbidity and successful management of adult ADHD. J Atten Disord (2012) 0.87
Time course and predictors of health-related quality of life improvement and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder treated with the methylphenidate transdermal system. J Child Adolesc Psychopharmacol (2010) 0.87
Occupational issues of adults with ADHD. BMC Psychiatry (2013) 0.87
Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs (2013) 0.86
An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr (2005) 0.86
Adult ADHD: prevalence of diagnosis in a US population with employer health insurance. Curr Med Res Opin (2011) 0.86
A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. J Med Econ (2010) 0.85
Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. Curr Med Res Opin (2011) 0.85
Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis. J Med Econ (2013) 0.84
Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. Prim Care Companion CNS Disord (2011) 0.84
Unmet needs associated with attention-deficit/hyperactivity disorder in eight European countries as reported by caregivers and adolescents: results from qualitative research. Patient (2015) 0.84
Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications. J Med Econ (2013) 0.84
Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. Patient (2012) 0.84
Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value Health (2011) 0.84
Management of adult attention deficit hyperactivity disorder in UK primary care: a survey of general practitioners. Health Qual Life Outcomes (2013) 0.83
Risk of injury associated with attention-deficit/hyperactivity disorder in adults enrolled in employer-sponsored health plans: a retrospective analysis. Prim Care Companion CNS Disord (2011) 0.83
Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD. J Atten Disord (2007) 0.83
Concomitant pharmacotherapy of psychotropic medications in EU children and adolescents with attention-deficit/hyperactivity disorder. Drugs R D (2013) 0.82
Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol (2012) 0.82
Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countries. Eur Child Adolesc Psychiatry (2014) 0.81
Development and validation of a disease-targeted quality of life instrument for chronic diverticular disease: the DV-QOL. Qual Life Res (2014) 0.81
Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. BMC Gastroenterol (2013) 0.81
HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Curr Med Res Opin (2009) 0.81
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Pharmacoeconomics (2012) 0.80
Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. J Med Econ (2012) 0.79
Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics. J Manag Care Pharm (2012) 0.79
Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults. J Med Econ (2013) 0.78
Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/hyperactivity disorder in Germany. Clin Ther (2013) 0.78
Preferences and utilities for the symptoms of moderate to severe allergic asthma. Eur J Health Econ (2007) 0.78
Automated identification of patients with a diagnosis of binge eating disorder from narrative electronic health records. J Am Med Inform Assoc (2013) 0.77
Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009. J Child Adolesc Psychopharmacol (2014) 0.77
Constipation-related direct medical costs in 16 887 patients newly diagnosed with chronic constipation. Eur J Gastroenterol Hepatol (2014) 0.77
Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder. Am J Manag Care (2014) 0.77
Prevalence and incidence of adult attention deficit/hyperactivity disorder in a large managed care population. Curr Med Res Opin (2014) 0.76
The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamine. Qual Life Res (2014) 0.76
Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. Curr Med Res Opin (2010) 0.75
Relationship between symptom impairment and treatment outcome in children and adolescents with attention-deficit/hyperactivity disorder: a physician perspective. Atten Defic Hyperact Disord (2014) 0.75
Cost of hospitalization for cerebrovascular disorders in Belgium. Acta Neurol Belg (2011) 0.75
Authors' reply to Alatorre et al.: "cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison". Appl Health Econ Health Policy (2013) 0.75
What influences clinicians' decisions about ADHD medication? Initial data from the Influences on Prescribing for ADHD Questionnaire (IPAQ). Eur Child Adolesc Psychiatry (2013) 0.75
Medical resource utilization and associated costs in patients with ulcerative colitis in the UK: a chart review analysis. Eur J Gastroenterol Hepatol (2014) 0.75
The activity of aminoacyl-tRNA synthetase-interacting multi-functional protein 1 (AIMP1) on endothelial cells is mediated by the assembly of a cytoskeletal protein complex. J Cell Biochem (2011) 0.75
Development and validation of algorithms to identify acute diverticulitis. Pharmacoepidemiol Drug Saf (2014) 0.75